Stryker Corporation
Stryker Corporation Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
2 of 4 strong
The short version
- Full-year 2026 organic net sales growth is expected in the range of 8% to 9.5%, despite the cyber incident disruption. - Full-year 2026 guidance maintained despite Q1 cyber incident; organic net sales growth expected at 8% to 9.5%.
From Stryker Corporation's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Full-year 2026 organic net sales growth is expected in the range of 8% to 9.5%, despite the cyber incident disruption.
- The company anticipates recovering most of the Q1 lost sales throughout the rest of the year, with rescheduled procedures and order fulfillment spreading into H2, especially for MedSurg capital products.
- Procedural volumes remain healthy, supported by favorable demographics and robotic-assisted surgery adoption.
- Hospital capital expenditure environment is steady, with an elevated capital order book expected to support growth.
- Mako installations hit a record Q1, with sustained momentum from installations and utilization projected to drive joint replacement business growth.
- Continued double-digit growth in Orthopaedics, with positive launches expected to accelerate growth in H2.
2 more points from Stryker Corporation's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Stryker Corporation said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans to make some investments related to recovery from the recent cyber incident; these investments are already factored into their current guidance. (Page 14)
- There is a creation of a new business unit called SmartCare aimed at "Smart Hospital" integration, which is expected to receive focused and increased investment moving forward. (Page 14)
- The company is actively evaluating M&A opportunities, especially in soft tissue robotics and sustainment solutions, which could be a form of strategic investment; they also recently completed the AVS acquisition to boost Peripheral Vascular business. (Pages 11, 6)
2 more points from Stryker Corporation's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Stryker Corporation said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has a very healthy order book despite shipment pauses caused by the cyber incident.
- There was no pause in orders during Q1; the shipment pause was due to inability to produce product for nearly 3 weeks.
- Hospitals maintain strong interest and healthy balance sheets, supporting continued orders.
- Capital order book remains elevated entering the remainder of the year.
- The company expects most lost sales from Q1 to be realized throughout the rest of 2026.
- Recovery of deferred procedures and order fulfillment will occur gradually, primarily in Q3 and Q4.
2 more points from Stryker Corporation's call on order book
Create a free account to keep reading this call
Continue your research
Others in Health Care Equipment and Supplies this season
- Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
- Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
- Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
- Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Stryker Corporation and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Stryker Corporation Q2 FY26 results?
- Full-year 2026 organic net sales growth is expected in the range of 8% to 9.5%, despite the cyber incident disruption. - Full-year 2026 guidance maintained despite Q1 cyber incident; organic net sales growth expected at 8% to 9.5%.
What is Stryker Corporation share price analysis?
Stryker Corporation currently shows a below-average growth signal. The stock trades at a P/E of 36.2 with a market cap of $117,933. Investors should review the full earnings analysis for detailed insights.
Is Stryker Corporation planning capital expenditure?
- The company plans to make some investments related to recovery from the recent cyber incident; these investments are already factored into their current guidance.
Keep Stryker Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.